Natalizumab (NTZ) is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. Pirogov Medical University took part in the analysis of patients receiving natalizumab and the efficacy of NTZ therapy in routine clinical practice in Russia. Data were collected in 2018 from 7 multiple sclerosis centers in 4 regions. Based on data for 334 patients, it was found that had a great impact on MS activity. Patients on NTZ had a significant decrease of relapse rate after 2 years of therapy.

Read more in

Evdoshenko E, Stepanova A, Shumilina M, Davydovskaya M, Khachanova N, Neofidov N, Kalinin I, Popova E, Dubchenko E, Pozhidaeva N, Volkov A, Sivertseva S, Prilenskaya A, Malkova N, Korobko D, Vergunova I, Shchur S, Makshakov G. Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia. PLoS One. 2019. 14(5):e0217303. doi: 10.1371/journal.pone.0217303.